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Abstract
Background: A long noncoding RNA (lncRNA) can act as a competing endogenous RNA (ceRNA) to compete with
an mRNA for binding to the same miRNA. Such an interplay between the lncRNA, miRNA, and mRNA is called a ceRNA
crosstalk. As an miRNA may have multiple lncRNA targets and multiple mRNA targets, connecting all the ceRNA
crosstalks mediated by the same miRNA forms a ceRNA network. Methods have been developed to construct ceRNA
networks in the literature. However, these methods have limits because they have not explored the expression
characteristics of total RNAs.
Results: We proposed a novel method for constructing ceRNA networks and applied it to a paired RNA-seq data set.
The first step of the method takes a competition regulation mechanism to derive candidate ceRNA crosstalks. Second,
the method combines a competition rule and pointwise mutual information to compute a competition score for each
candidate ceRNA crosstalk. Then, ceRNA crosstalks which have significant competition scores are selected to
construct the ceRNA network. The key idea, pointwise mutual information, is ideally suitable for measuring the
complex point-to-point relationships embedded in the ceRNA networks.
Conclusion: Computational experiments and results demonstrate that the ceRNA networks can capture important
regulatory mechanism of breast cancer, and have also revealed new insights into the treatment of breast cancer. The
proposed method can be directly applied to other RNA-seq data sets for deeper disease understanding.
Keywords: Competing endogenous RNA, Pointwise mutual information, Competition rule
Background
Long non-coding RNAs (lncRNAs) are involved in a vari-
ety of biological functions [1]. However, not much is
known about the functions and regulatory mechanisms
of non-coding RNAs with other types of RNAs [2]. Some
early studies [3, 4] found that a RNA can influence the
expression level of other RNAs by competing to bind to
the same miRNA. Based on these early findings, Pan-
dolfi proposed a competing endogenous RNA (ceRNA)
hypothesis [5]. This ceRNA hypothesis stated that non-
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coding RNAs and coding RNAs would widely compete
with mRNAs for binding to the same miRNAs. This
ceRNA hypothesis not only provides a reasonable justifi-
cation for the presence of lncRNA, it also provides a new
and global function map of lncRNA [6], explaining the
regulatory function of 3′ UTRs [5]. Recent experiments
have provided new evidence for this hypothesis. For exam-
ple, BRAFP1 can compete with gene BRAF for binding to
the same miRNA hsa-miR-543 in lymphoma [7]; PTENP1
can compete with gene PTEN for binding to the same
miRNA hsa-miR-17-5p in hepatocellular carcinoma [8].
Both non-coding RNAs and coding RNAs can act as ceR-
NAs according to the ceRNA hypothesis. We focus on the
investigation of long non-coding ceRNAs in this work.
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When a lncRNA acts as a ceRNA to compete with
an mRNA for binding to the same miRNA, this inter-
play between the lncRNA, miRNA, and mRNA is called
a ceRNA crosstalk. An miRNA may have multiple target
lncRNAs and it can also regulate several differentmRNAs,
therefore, there can exist many crosstalks mediated by this
miRNA to form a ceRNA network. Such a network is use-
ful for detecting cancer biomarkers [9], patterns for early
diagnosis [10], and new concepts for cancer treatment
[11].
Every lncRNA in a ceRNA network has three common
characteristics [5]. First, changes in the ceRNA expression
levels are wide, or they are highly differentially expressed,
between tumor and normal samples. Second, the lncRNA
is the primary target of the miRNA. Third, the relation-
ships between the lncRNA, miRNA, and mRNA should
obey a competition rule in the ceRNA network. The com-
petition rule states that when the expression level of the
ceRNA is very high, the ceRNA can compete for bind-
ing to the miRNA and decrease the expression level of
the miRNA. Since miRNA has a low expression level, less
number of miRNAs bind to its target mRNA. Therefore,
the expression level of the mRNA becomes high. In con-
trast, when the expression level of the ceRNA is very low,
the expression level of the miRNA will be high; a high
expression level of miRNA leads to a low expression level
of mRNA.
Many methods for constructing ceRNA networks have
been developed and they can be grouped into two cate-
gories. As the ceRNA is the primary target of miRNA, the
first category of method is based on predicting the target
of the miRNA. Traditional methods apply the sequence
alignment and the free energy models to discover the pri-
mary targets of miRNAs, such as the method TargetScan
[12]. However, these methods have a high false positive
rate. Later methods employ extra data sets and multiple
algorithms to decrease the false positive rate, for exam-
ple, Sardina’s method [13]. These methods only apply the
sequence of miRNA and miRNA targets and do not cal-
culate the expression relationship between miRNAs and
miRNA targets. Thus, these methods still have a high false
positive rate. Xia’s method identifies the overexpressed
lncRNAs from the expression data, but do not con-
sider the competitive relationship between the lncRNA,
miRNA, and mRNA [14]. Several methods utilize the
Pearson coefficient to find out the competitive relation-
ship between lncRNA, miRNA, and mRNA, e.g., Paci’s
method [15]. However, the Pearson coefficient is not suit-
able for measuring non-linear relationship. An miRNA
could bind to multiple targets, the competitive relation-
ship between RNAs is not always linear. These methods
neglect the ceRNA networks which pose non-linear rela-
tionships. A few methods can measure the non-linear
relationship between lncRNA, miRNA, andmRNA but do
not consider the overexpressed RNAs, for example, Zhou’s
method [16] and Zhang’s method [17]. These methods
could identify a lot of ceRNA networks but a few ceRNA
networks regulating cancer processes. Other methods
such as Chiu’s method [18] discover the pair-wised rela-
tionship between two RNAs then use the pair-wised
relationship to construct the ceRNA network. The pair-
wised relationship is the relationship between two RNAs
rather than the competitive relationship between lncRNA,
miRNA, and mRNA. The ceRNA network reflects the
competition relationship between lncRNA, miRNA, and
mRNA. Using these methods to construct ceRNA net-
work may produce some false positives of ceRNA net-
works. Above all, these two types of methods for pre-
dicting ceRNA networks have their limitations. A novel
method is demanded to improve the predictions.
We propose a novel method for constructing ceRNA
networks from paired RNA-seq data sets. This method
identifies the over expressed lncRNAs from the lncRNA
expression data of the normal and tumor samples. Thus,
we can identify the ceRNA network related to breast can-
cer. Then, the competitive relationships between the lncR-
NAs, miRNAs, and mRNAs are established by using the
expression levels of the lncRNAs, miRNAs, and mRNAs
in the tumor samples. We combine the competition rule
and pointwise mutual information to calculate a competi-
tion score for each of the ceRNA crosstalks. As an miRNA
can have many ceRNAs and can bind to multiple mRNAs,
the competitive relationship between lncRNA, miRNA,
and mRNA is non-linear. Pointwise mutual information is
suitable for measuring the complex point-to-point com-
petitive relationship between RNAs.
Results
We report two important ceRNA networks related to
breast cancer and reveal their characteristics. We also
report how these ceRNA networks play vital roles in
KEGG pathways. Comparison results with the literature
construction methods are presented at the Additional
file 1.
Two important ceRNA networks related to breast cancer
Our method identified 352 mRNAs, 24 miRNAs, and 136
lncRNAs which are differentially expressed between the
tumor and normal tissues. As there are 4 of these miR-
NAs which do not have any predicted target RNAs in the
RNAwalker2.0 database, ceRNA networks mediated by
the remaining 20 miRNAs which have target RNAs in the
database are constructed. The 20 miRNAs are: hsa-miR-
200a-5p, hsa-miR-203a-3p, hsa-miR-33a-5p, hsa-miR-21-
3p, hsa-miR-183-5p, hsa-miR-144-5p, hsa-miR-145-5p,
hsa-miR-184, hsa-miR-451a, hsa-miR-9-3-5p, hsa-miR-
182-5p, hsa-miR-940, hsa-miR-375, hsa-miR-5683, hsa-
miR-3677-3p, hsa-miR-429, hsa-miR-486-2-5p, hsa-miR-
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210-3p, hsa-miR-335-5p, hsa-miR-196a-2-5p, hsa-miR-
21-5p, hsa-miR-378a-3p, hsa-miR-3065-5p, and hsa-miR-
142-3p. The total number of candidate ceRNA crosstalks
mediated by these 20 miRNAs is 75501.
To narrow down the study, we focus our analysis on two
significant ceRNA networks: one is mediated by hsa-miR-
451a, and the other is mediated by hsa-miR-375. These
two miRNAs have a vital role in regulating breast cancer
as reported in literature [19, 20], but their ceRNA net-
works have not been investigated previously. Our point-
wise mutual information based method detected 132 can-
didate ceRNA crosstalks mediated by hsa-miR-451a and
1547 candidate ceRNA crosstalks mediated by hsa-miR-
375. Of them, 25 candidate ceRNA crosstalks mediated
by hsa-miR-451a have significant competition scores and
only 273 candidate ceRNA crosstalks mediated by hsa-
miR-375. We use these ceRNA crosstalks which have
significant competition scores to construct the ceRNA
networks. Fig. 1 is the ceRNA network mediated by hsa-
miR-451a and Fig. S2 (in the Additional file 1) presents the
ceRNA network mediated by hsa-miR-375.
Characteristics of the two ceRNA networks
The two ceRNAnetworks are satisfied with the three char-
acteristics of ceRNA networks: (1) the expression level of
every lncRNA between the normal and tumor samples
is highly differential, (2) every lncRNA is a target of the
miRNA, and (3) the expression levels of lncRNA, mRNA
andmiRNA follow the competition rule. The absolute fold
change of these lncRNAs in ceRNA crosstalks mediated
by hsa-miR-451a and hsa-miR-375 are larger than 3.0 and
the p-values are smaller than 0.01. This means that these
lncRNAs are over-expressed and satisfy the first point of
characteristics of a ceRNA network. Table S3 presents the
detailed expression fold change and the p-values of these
lncRNAs.
When a lncRNA competes with an mRNA for binding
to the same miRNA, the lncRNA and the mRNA both
are the targets of the miRNA. We examined the seed
regions of hsa-miR-451a to see whether its target mRNAs
or lncRNAs are complementary to the seed region in
sequence [21]. ENSG00000272620 is perfectly comple-
mentary to the seed region of hsa-miR-451a, and mRNA
DLX6 is complementary to the seed region of the hsa-
miR-451a with one mismatch pair. This suggests that
lncRNA ENSG00000272620 and mRNA DLX6 should be
very likely the targets of hsa-miR-451a. Fig. S3 (in the
Additional file 1) shows the binding region of lncRNA
ENSG00000272620 and hsa-miR-451a and the binding
region of mRNA DLX6 and hsa-miR-451a.
Table 1 shows the top 5 competition scores of the
crosstalks mediated by hsa-miR-451a and hsa-miR-375, as
calculated by our pointwise mutual information method.
A different ceRNA network has a different competition
score. Some of the ceRNA competition scores may be
similar. For example, the largest competition score of
the ceRNA crosstalk mediated by hsa-miR-451a is equal
with the competition score of the ceRNA crosstalk medi-
ated by hsa-miR-375. But some competition score of the
ceRNA crosstalk is not very similar. Such as the largest
Fig. 1 A ceRNA network mediated by hsa-miR-451a. The rectangle and oval boxes contain the names of lncRNAs and mRNAs, respectively
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Table 1 Top-5 competition scores in the ceRNA crosstalks
mediated by hsa-miR-375 and hsa-miR-451a
lncRNA miRNA mRNA Score P-value
ENSG00000277199 hsa-miR-375 GFRAL 0.35 6.76 ∗ 10−236
ENSG00000238099 hsa-miR-375 C6orf58 0.35 8.48 ∗ 10−228
ENSG00000279204 hsa-miR-375 SOX17 0.31 1.51 ∗ 10−184
ENSG00000229108 hsa-miR-375 DUXA 0.30 2.56 ∗ 10−171
ENSG00000277199 hsa-miR-375 MEOX2 0.30 3.27 ∗ 10−167
ENSG00000272620 hsa-miR-451a DLX6 0.35 8.88 ∗ 10−45
ENSG00000279184 hsa-miR-451a ZG16 0.32 1.60 ∗ 10−37
ENSG00000272620 hsa-miR-451a INSM1 0.31 3.89 ∗ 10−35
ENSG00000272620 hsa-miR-451a NTSR1 0.30 4.92 ∗ 10−33
ENSG00000272620 hsa-miR-451a GPR26 0.30 4.92 ∗ 10−33
competition score of the ceRNA crosstalk mediated by
hsa-miR-21-5p is 0.53 which is larger than the largest
competition score of ceRNA crosstalk mediated by hsa-
miR-451a. However, if two ceRNA crosstalks aremediated
by the same miRNA, the higher competition score of the
ceRNA crosstalk is, the more reliable the crosstalk is.
ceRNA networks and breast cancer treatment
The ceRNA crosstalks mediated by hsa-miR-375 or by
hsa-miR-451a may regulate the development of breast
cancer. These ceRNA crosstalks should be considered in
the future for the treatment plan of breast cancer.
As suggested in the third row of Table 1,
ENSG00000279204 competes with SOX17 for binding
to hsa-miR-375. SOX17 is a member of the SRY-related
HMG-box family that can regulate cell development [22].
Fu. et al found that increasing the expression level of this
gene can slow down the speed of breast cancer growth;
but reducing the expression level of this gene can lead to
poor survival outcomes in breast cancer patients [23].
Thus SOX17 can be a useful biomarker for breast cancer
patients. It can be also understood that the expression
of SOX17 can be up-regulated with the increase of the
expression of ENSG00000279204. A high expression level
of SOX17 would lead to decreased growth of breast can-
cer cell so as to improve the treatment of breast cancer
patients.
The gene MEOX2 is also called GAX or MOX2. This
gene is down-regulated in breast cancer [24]. Recent
research shows that MEOX2 can up-regulate p21 which
is very important for breast tumor grading [25]. Highly
expressed p21 prevents the growth of breast cancer [26].
As shown in the fifth line of Table 1, ENSG00000229108
competes with MEOX2 for binding with hsa-miR-375.
The high expression level of MEOX2 can enhance the
growth of breast cancer. Therefore, decreasing the expres-
sion level of ENSG00000229108 can reduce the expression
level ofMEOX2. Thus the high expression level ofMEOX2
would inhibit the growth of breast cancer.
In the last second line of Table 1, ENSG00000272620
competes with NTSR1 for binding with hsa-miR-451a.
NTSR1 is a target of the Wnt/APC oncogenic pathways
which is involved in cell proliferation and transforma-
tion [27]. Dupouy found that highly expressed NTSR1 is
associated with the size, the number of metastatic lymph
nodes, and Scarff-Bloom-Richardson grading [28]. These
suggest thatNTSR1 is a promising target for breast cancer
treatment. According to the predicted results, decreasing
the expression level of ENSG00000272620 can decrease
the expression level of NTSR1. Low expression level of
NTSR1 is beneficial for the treatment of breast cancer.
Most breast cancer patients die because of the “incur-
able” nature of the metastasis breast cancer [29]. About
90% of breast cancer deaths are due to metastasis;
indeed, only 20% of the metastatic breast cancer patients
can survive more than 1 year [30]. Therefore, inhibit-
ing breast cancer metastasis is very crucial for breast
cancer treatment. Morini found that DLX6 involves in
the metastasis potential of breast cancer [31]. Prest
also pointed out that TFF1 can promote breast can-
cer cell migration [32]. These studies imply that DLX6
and TFF1 are highly related to breast cancer metas-
tases. Therefore, decreasing the expression level of these
two genes can inhibit breast cancer metastasis. Accord-
ing to our results, lncRNA ENSG00000272620 and
ENSG00000279184 cross-regulate DLX6 and TFF1 via
hsa-miR-451a, respectively. Decreasing the expression
level of ENSG00000272620 and ENSG00000279184 can
decline the expression levels of DLX6 and TFF1. The low
expression levels of these two genes would prevent the
development of metastatic breast cancer.
Roles of ceRNA networks in KEGG pathways
Some lncRNAs can cross-regulate genes which
are involved in Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways. Enrichr [33], a gene enrich-
ment analysis web server, is applied to find out these
KEGG pathways [34]. 14 KEGG pathways are found with
p-values lower than 0.05. Some of these KEGG pathways
are the key pathway in regulating breast cancer and may
be a potential drug target for breast cancer treatment,
such as the chemokine signaling pathway, the cytokine-
cytokine receptor interaction, and the neuroactive
ligand-receptor interaction [35–37]. All the KEGG path-
ways are presented in Table. S4 (in the Additional file 1).
In this subsection, we focus on analyzing the chemokine
signaling pathway.
The cross regulation between the lncRNAs and the
genes involved in the chemokine signaling pathway is
shown in Fig. 2, demonstrating 11 genes related to
chemokine signaling pathway are involved in breast
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cancer. Of them, CXCL10, CXCL9, CCL11, CCR8, and
GNG13 up-regulate breast cancer, while the other genes
download-regulate breast cancer. Chemokine signaling
pathway expresses on the immune cells and regulates
immune responder. However, new evidences show that
the gene in the chemokine signaling pathway also plays
a vital role in breast cancer progression [36]. For exam-
ple, CXCL10 affects the tumor microenvironment and
plays important role in breast cancer progression [38],
CXCL9 is identified as a biomarker in breast cancer [39].
Regulating these gene can inhibit the growth of breast
cancer.
A ceRNA which may be an efficient drug target for breast
cancer treatment
Two different miRNAs may have common target mRNAs
and common target lncRNAs. A common target lncRNA
can cross-regulate mRNAs through different miRNAs.
Therefore, this common target lncRNA is an efficient
drug target for cancer treatment. An example can be
found in Fig. 3. The lncRNA ENSG00000261742 com-
petes for binding to hsa-miR-21-5p, hsa-miR-33a-5p, and
hsa-miR-184 with HOXA5 and EGR1. EGR1 is known to
up-regulate PTEN which is a key tumor breast suppressor
gene [40]. It implies that increasing the expression level
of EGR1 can suppress the development of breast cancer.
The lowly expressed HOXA5 lead to the functional acti-
vation of twist and promoting the development of breast
cancer [41]. Therefore, increasing the expression level of
these two mRNAs are very important for breast cancer
treatment.
Hsa-miR-21-5p, hsa-miR-33a-5p, and hsa-miR-184 can
regulate the expression of these two mRNAs. However,
only decreasing the expression level of onemiRNA cannot
enhance the expression levels of these two mRNAs, since
the high expression of the other miRNA can decrease
the expression of both mRNAs. In our results, increas-
ing the expression of ENSG00000261742 can enhance the
expression of these two mRNAs by decreasing the expres-
sion of these two miRNAs. Therefore, ENSG00000261742
is an efficient drug target for increasing the expres-
sion of both mRNAs. About all, this ceRNA is sug-
gested to be an efficient drug target for breast cancer
treatment.
Discussion
The ceRNA hypothesis is still in its infancy, many ceRNA
networks have not been discovered yet. The mutations of
miRNA may change existing or lead to new crosstalk. For
example, the 5′ variant of miRNA may bind to different
target mRNA or lncRNA comparing to its wildtype
miRNA since the shift of the seed region of the miRNA.
Further, the ceRNA hypothesis illustrates the complex-
ity of RNA regulatory network. By this hypothesis, some
other complexity networks may exist. Our method for
discovering ceRNA network from the RNA-seq data that
contains the expression level of RNA (miRNA, lncRNA,
and mRNA) is limited to only the tumor and normal
tissues, how to incorporate different tissues that have a
matching RNA and miRNA sequencing data set to extend
our analysis is a future direction of our research in this
area.
A lncRNA that is not differentially expressed may con-
tribute to the sponge mechanism as well [42]. In par-
ticular, the relative concentration of the ceRNAs and
changes in the ceRNA expression levels are very impor-
tant for discovering ceRNA networks [5]. Indeed, condi-
tions like the relative concentration of ceRNAs and their
microRNAs or other conditions not necessarily corre-
sponding to differentially expressed RNAs can be appli-
cable as starting points to discover ceRNAs. These will
be some of our future work to enrich the ceRNA sponge
hypothesis.
Conclusion
In this paper, we proposed a novel method for con-
structing ceRNA networks from paired RNA-seq data
sets. We first identify the differentially expressed lncR-
NAs, miRNAs, and mRNAs from the paired RNA-seq
data sets. Then we derive the competition regulation
mechanism from the competition rule and construct the
candidate ceRNA crosstalks based on this rule. This com-
petition regulation mechanism is another feature of the
ceRNA network and is useful for constructing ceRNA
networks. Finally, the pointwise mutual information is
applied to measure the competitive relationship between
these RNAs to select reliable ceRNA crosstalks to con-
struct the ceRNA networks. The analysis results have
shown that the function of ceRNA networks is related to
the growth, proliferation, and metastatic of breast cancer.
These ceRNA networks present the complex regulatory
mechanism of the RNAs in breast cancer. In addition,
the ceRNA networks suggest a new approach for breast
cancer treatment.
Method
Our method for constructing ceRNA network has four
steps. Firstly, it computes the expression levels of lncRNA,
miRNA, and mRNA from the breast cancer tumor tissues
and normal tissues. Secondly, the predicted miRNA tar-
gets, differentially expressed RNAs, and the competition
regulation mechanism are used to construct the candidate
ceRNA networks. Thirdly, it combines the competition
rule and the pointwise mutual information to compute the
competition score of each ceRNA crosstalk. Finally, we
select the ceRNA crosstalks which have significant com-
petition scores to construct the ceRNA network. Fig. 4
shows the framework of our method.
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Fig. 2 The ceRNA networks involved in the chemokine signaling pathway
Definitions and data preprocessing
If a lncRNA lnc competes with an mRNA mr for bind-
ing to an miRNA mir, the triple of lnc, mir, and mr is
called a ceRNA crosstalk denoted by T = (lnc,mir,mr).
We also say that ceRNA crosstalk T = (lnc, mir, mr) is
mediated bymir. For example, Fig. 5a is a ceRNA crosstalk
T = (lncRNA1,miRNA,mRNA1) mediated bymiRNA.
All the ceRNA crosstalks mediated by the same miRNA
as a whole is defined as a ceRNA network. It is denoted by
N = (lnR, mir, mR), where lnR stands for the set of lncR-
NAs, mir is the miRNA, and the mR stands for the set of
mRNAs. We also say ceRNA network N = (lnR,mir,mR)
is mediated by mir. For example, Fig. 5b is a ceRNA net-
work, where lnR = {lncRNA1, lncRNA2, . . . , lncRNAn}
andmR = {mRNA1,mRNA2, . . . ,mRNAm}.
The paired breast cancer RNA-seq data set was down-
loaded from the TCGA GDC data portal website [43].
This paired data set contains the expression levels of lncR-
NAs, mRNAs, and miRNAs of 102 tumor and normal
tissue samples. The TCGA IDs of these 102 samples are
listed in Additional file 1: Table S5. These RNAs and their
expression levels form an expression matrix. Table S1 is
an example of expressionmatrix. Some RNAs expresses in
only a few tissue samples. These low frequently expressed
RNAs are not important for breast cancer study and may
have noise affect to the result. Thus, these RNAs which
are not expressed in half of the whole tissue samples were
removed from the expression matrix. We transform the
expression matrix to a binary expression matrix by using
the equal frequency discretization method: for the same
RNA expressed in all samples, if this RNA expression level
of a sample is higher (lower) than themedian RNA expres-
sion level of all the samples, this RNA is highly (lowly)
expressed in this sample and is assigned with binary value
1 (0). This process was conducted using Weka3.8 [44].
Let I[R, S] denotes the binary expression matrix, where
R is the set of RNAs from the original data set after the
noise removal, and S is the set of samples. In the binary
expression matrix, 1 represents that the expression level
of the RNA is relatively high, 0 means that the expression
level of the RNA is relatively low. Table S2 is the binary
expression matrix transformed from Table S1.
For a given binary expression matrix I[R, S], we define
that r′ is a RNA from R and sa′ is a sample from S.
Fig. 3 A ceRNA network cross-regulates two mRNAs through three miRNAs
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I[ r′, sa′] is the value of the RNA r′ of the sample sa′ in the
binary expression matrix I[R, S]. For example, in Table S2,
I[ lnc1, sa1] is 0 and I[mrm, sa2] is 1.
Constructing a candidate ceRNA network
The target mRNAs and lncRNAs of the miRNAs were
downloaded from the miRWalk2.0 database [45]. The
miRWalk2.0 database contains the comparison results of
binding sites from 12 existing miRNA-target prediction
software tools [46]. It is a high quality database of miRNA
targets. Also, this database contains the miRNA’s target
lncRNAs and target mRNAs. An miRNA (with p-value
≤ 0.05 and absolute fold change ≥ 2.0), its target lncR-
NAs (with p-value ≤ 0.05 and absolute fold change ≥ 3.0)
and its target mRNAs (with p-value ≤ 0.05 and absolute
fold change ≥ 2.0) are used to construct the initial ceRNA
network. The differentially expressed lncRNA, miRNA,
and mRNA are computed by using fold change [47] and
the t-test method [48].
Suppose a lncRNA lnc, an miRNA mir, and an mRNA
mr form a ceRNA crosstalk. If lnc up-regulates in breast
cancer samples, then the fold change of lnc should be
larger than 0. According to the competition rule, the
highly expressed lncRNA can lead to low expression of the
miRNA, i.e., mir down-regulates and the fold change of
mir should be smaller than 0. The low expression level of
the miRNA increases the expression level of the mRNA.
Therefore, mr up-regulates in the breast cancer samples,
and the fold change of mr should be larger than 0. Sim-
ilarly, if lnc down-regulates and the fold change of lnc is
smaller than 0, then mir up-regulates in the breast cancer
samples and the fold change of mir should be larger than
0. Then mr down-regulates in the breast cancer tumor
and the fold change of mr is smaller than 0. Based on
this principle, we propose a competition regulation mech-
anism. This competition regulation mechanism is divided
into a positive and a negative competition regulation
facet:
• Positive competition regulation mechanism: the fold
change of the miRNA is larger than 0, and the fold
changes of lncRNAs and mRNAs are smaller than 0.
• Negative competition regulation mechanism: the fold
change of the miRNA is smaller than 0, the fold
changes of lncRNAs and mRNAs are larger than 0.
Given the initial ceRNA network, we find the lncRNAs
and mRNAs which follow the positive or negative compe-
tition regulation mechanism. Then the miRNA, the rest
of the lncRNAs andmRNAs construct a candidate ceRNA
network. We denote the candidate ceRNA network by
N ′ = (lncR, mir, mR), where lncR and mR stand for the
sets of lncRNAs or mRNAs which follow the competition
regulation mechanism.
Fig. 4 The framework of our method
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Fig. 5 a A ceRNA crosstalk; b A ceRNA network
Computing the competition score
A candidate ceRNA network is formed by combining
many ceRNA crosstalks. Some of these candidate ceRNA
crosstalks may not satisfy the competitive relationship.
Pointwise mutual information was proposed to measure
the relationships between individual words in a corpus
[49]. If two words frequently co-occur, the pointwise
mutual information is high. In this work, we apply it
to measure the competitive relationships between RNAs
in a ceRNA network, namely if a lncRNA can cross
regulate an mRNA through an miRNA, the pointwise
mutual information of this crosstalk should be high. Tra-
ditional pointwise mutual information utilizes the prob-
ability coincidence or Gaussian kernel to measure the
relationship between the variables; and only a positive
or only a negative score between the variables is calcu-
lated. However, the competitions in a ceRNA crosstalk
have both negative and positive relationships between the
two RNAs. Therefore, the traditional pointwise mutual
information needs to be refined for measuring the com-
petition relationships between the RNAs in a ceRNA
crosstalk. In this work, we calculate the pointwise mutual
information based on our competition rule, as detailed
below.
Given a candidate ceRNA network N ′ = (lncR, mir,
mR), where lncR = {lnc1, lnc2, . . . , lncn} and mR = {mr1,
mr2, . . . , mrm}, any lncRNA lnci ∈ lncR, mir, and any
mRNA mrj ∈ mR can form a ceRNA crosstalk T = (lnci,
mir, mrj). We use a competition score to measure the
reliability of each ceRNA crosstalk. The higher the com-
petition score of the ceRNA crosstalk is, the more reliable
the ceRNA crosstalk is.
Given a binary expression matrix I[R, S], let lnci, mir,
and mrj be a lncRNA, an miRNA, and an mRNA of R,
respectively, and let sal be one of the samples in S. If
lnci, mir, and mrj in sal are satisfied with one of these
conditions:
• Condition 1: I[ lnci, sal]= 0, I[mir, sal]= 1, and
I[mrj, sal]= 0.
• Condition 2: I[ lnci, sal]= 1, I[mir, sal]= 0, and
I[mrj, sal]= 1.
we say that sal is the competition sample of T =
(lnci,mir,mrj). For example, at Table S2, sa1 is a compe-
tition sample of T = (lnc1,mir1,mr1), since I[ lnc1, sa1]=
0, I[mir1, sa1]= 1, and I[mr1, sa1]= 0. In addition, we
define that suppS(lnci,mir,mrj) is the total number of the
competition samples of T = (lnci,mir,mrj) in the sample
set S.
The competition score of T = (lnci,mir,mrj) is com-
puted by using pointwise mutual information:
PMISmir(lnci,mrj) = log
PSmir(lnci,mrj)
PSmir(lnci)PSmir(mrj)
where PSmir(lnci,mrj), PSmir(lnci), and PSmir(mrj) are com-
puted by:
PSmir(lnci,mrj) =
suppS(lnci,mir,mrj)
∑n
i′=1
∑m
j′=1 suppS(lnci′ ,mir,mrj′)
PSmir(lnci) =
∑m
j′=1 suppS(lnci,mir,mrj′)
∑n
i′=1
∑m
j′=1 suppS(lnci′ ,mir,mrj′)
PSmir(mrj) =
∑n
i′=1 suppS(lnci′ ,mir,mrj)∑n
i′=1
∑m
j′=1 suppS(lnci′ ,mir,mrj′)
A positive pointwise mutual information means the
variables co-occur more frequently than what would be
expected under an independence assumption, and a neg-
ative pointwise mutual information means the variables
co-occur less frequently than what would be expected.
Selecting a crosstalk which has a significant competition
score
A competition score can be 0, negative, or positive. If
the competition score of a ceRNA crosstalk is 0 or neg-
ative, it implies that there is no competitive relationship
between the lncRNA, miRNA, and mRNA or the com-
petitive relationship is less reliable than we would be
expected. Such a ceRNA crosstalk should be discarded.
A positive competition score indicates that the competi-
tive relationship between these RNAs ismore reliable than
what we expected, and thus the ceRNA crosstalk is reliable
to construct the ceRNA network. Further, the higher the
competition score, the more reliable the ceRNA crosstalk
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is. Therefore, we should select those crosstalks which are
reliable enough to construct the ceRNA network.
Suppose we are given t candidate ceRNA crosstalks
and their competition scores are {PMI1, PMI2, . . . , PMIt}
which are all positive. A threshold θ is applied to distin-
guish low and high competition scores, and the problem
is to reject the null hypothesis. The null hypothesis is
that the competition score is small, that is, it implies
there is no competing relationship in this crosstalk. If the
competing score is very high, the null hypothesis can be
rejected—it implies that this ceRNA crosstalk involves in
regulating the biological process. For a ceRNA crosstalk a,
its significance level θa of the competition score is:
θa = PMIa − PMI
σ
where PMI and σ are the average and standard devi-
ation of the entire competition scores. The p-value of
the ceRNA crosstalk a is pa = erfc(θa/
√
2) [50]. If the
p-value of a ceRNA crosstalk is lower than 0.05, this
ceRNA crosstalk has significant competition score. We
select those ceRNA crosstalks which have significant com-
petition scores to construct the ceRNA network.
The novelty of our method is to apply competition
regulation mechanism to construct candidate ceRNA net-
works and utilize the pointwise mutual information to
calculate the competition scores. The competition regula-
tion mechanism, which is deducted from the competition
rule, reflects the nature of the competition rule. There-
fore, this regulation mechanism is a critical feature of the
ceRNA network and can be applied to filter out many
noisy eRNAs. Pointwise mutual information can measure
both non-linear and linear relationship, and it is suitable
for calculating the competition score of ceRNA crosstalks.
Further, our method utilizes the pointwise mutual infor-
mation to measure the point-to-point competitive rela-
tionships between lncRNA, miRNA, and mRNA, but not
the pair-wise relationship between the two RNAs.
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